Taiwan · Delayed Price · Currency is TWD BioLASCO Taiwan Statistics
Total Valuation
BioLASCO Taiwan has a market cap or net worth of TWD 779.89 million. The enterprise value is 752.58 million.
| Market Cap | 779.89M |
| Enterprise Value | 752.58M |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | Aug 7, 2025 |
Share Statistics
BioLASCO Taiwan has 25.61 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 25.61M |
| Shares Outstanding | 25.61M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 29.51% |
| Owned by Institutions (%) | n/a |
| Float | 16.85M |
Valuation Ratios
The trailing PE ratio is 17.43.
| PE Ratio | 17.43 |
| Forward PE | n/a |
| PS Ratio | 2.81 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | 20.74 |
| P/OCF Ratio | 12.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.47, with an EV/FCF ratio of 20.01.
| EV / Earnings | 16.82 |
| EV / Sales | 2.72 |
| EV / EBITDA | 11.47 |
| EV / EBIT | 13.77 |
| EV / FCF | 20.01 |
Financial Position
The company has a current ratio of 3.66, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.66 |
| Quick Ratio | 3.05 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.53 |
| Debt / FCF | 2.68 |
| Interest Coverage | 28.19 |
Financial Efficiency
Return on equity (ROE) is 10.09% and return on invested capital (ROIC) is 11.18%.
| Return on Equity (ROE) | 10.09% |
| Return on Assets (ROA) | 5.89% |
| Return on Invested Capital (ROIC) | 11.18% |
| Return on Capital Employed (ROCE) | 10.36% |
| Revenue Per Employee | 3.05M |
| Profits Per Employee | 491,615 |
| Employee Count | 91 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 5.72 |
Taxes
In the past 12 months, BioLASCO Taiwan has paid 11.10 million in taxes.
| Income Tax | 11.10M |
| Effective Tax Rate | 19.88% |
Stock Price Statistics
The stock price has decreased by -10.44% in the last 52 weeks. The beta is 0.19, so BioLASCO Taiwan's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -10.44% |
| 50-Day Moving Average | 31.02 |
| 200-Day Moving Average | 32.77 |
| Relative Strength Index (RSI) | 45.82 |
| Average Volume (20 Days) | 13,223 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLASCO Taiwan had revenue of TWD 277.12 million and earned 44.74 million in profits. Earnings per share was 1.75.
| Revenue | 277.12M |
| Gross Profit | 115.48M |
| Operating Income | 54.91M |
| Pretax Income | 55.84M |
| Net Income | 44.74M |
| EBITDA | 64.04M |
| EBIT | 54.91M |
| Earnings Per Share (EPS) | 1.75 |
Balance Sheet
The company has 127.96 million in cash and 100.66 million in debt, with a net cash position of 27.30 million or 1.07 per share.
| Cash & Cash Equivalents | 127.96M |
| Total Debt | 100.66M |
| Net Cash | 27.30M |
| Net Cash Per Share | 1.07 |
| Equity (Book Value) | 442.94M |
| Book Value Per Share | 17.29 |
| Working Capital | 145.69M |
Cash Flow
In the last 12 months, operating cash flow was 63.89 million and capital expenditures -26.28 million, giving a free cash flow of 37.61 million.
| Operating Cash Flow | 63.89M |
| Capital Expenditures | -26.28M |
| Free Cash Flow | 37.61M |
| FCF Per Share | 1.47 |
Margins
Gross margin is 41.67%, with operating and profit margins of 19.81% and 16.14%.
| Gross Margin | 41.67% |
| Operating Margin | 19.81% |
| Pretax Margin | 20.15% |
| Profit Margin | 16.14% |
| EBITDA Margin | 23.11% |
| EBIT Margin | 19.81% |
| FCF Margin | 13.57% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 4.91%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 4.91% |
| Dividend Growth (YoY) | -9.09% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 85.88% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 4.95% |
| Earnings Yield | 5.74% |
| FCF Yield | 4.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 30, 2018. It was a forward split with a ratio of 1.055.
| Last Split Date | Jul 30, 2018 |
| Split Type | Forward |
| Split Ratio | 1.055 |
Scores
BioLASCO Taiwan has an Altman Z-Score of 5.08 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.08 |
| Piotroski F-Score | 6 |